Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme
© Paskaleva et al; licensee BioMed Central Ltd. 2006
Received: 07 November 2005
Accepted: 25 May 2006
Published: 25 May 2006
The high rate of HIV-1 mutation and increasing resistance to currently available antiretroviral (ART) therapies highlight the need for new antiviral agents. Products derived from natural sources have been shown to inhibit HIV-1 replication during various stages of the virus life cycle, and therefore represent a potential source of novel therapeutic agents. To expand our arsenal of therapeutics against HIV-1 infection, we investigated aqueous extract from Sargassum fusiforme (S. fusiforme) for ability to inhibit HIV-1 infection in the periphery, in T cells and human macrophages, and for ability to inhibit in the central nervous system (CNS), in microglia and astrocytes.
S. fusiforme extract blocked HIV-1 infection and replication by over 90% in T cells, human macrophages and microglia, and it also inhibited pseudotyped HIV-1 (VSV/NL4-3) infection in human astrocytes by over 70%. Inhibition was mediated against both CXCR4 (X4) and CCR5 (R5)-tropic HIV-1, was dose dependant and long lasting, did not inhibit cell growth or viability, was not toxic to cells, and was comparable to inhibition by the nucleoside analogue 2', 3'-didoxycytidine (ddC). S. fusiforme treatment blocked direct cell-to-cell infection spread. To investigate at which point of the virus life cycle this inhibition occurs, we infected T cells and CD4-negative primary human astrocytes with HIV-1 pseudotyped with envelope glycoprotein of vesicular stomatitis virus (VSV), which bypasses the HIV receptor requirements. Infection by pseudotyped HIV-1 (VSV/NL4-3) was also inhibited in a dose dependant manner, although up to 57% less, as compared to inhibition of native NL4-3, indicating post-entry interferences.
This is the first report demonstrating S. fusiforme to be a potent inhibitor of highly productive HIV-1 infection and replication in T cells, in primary human macrophages, microglia, and astrocytes. Results with VSV/NL4-3 infection, suggest inhibition of both entry and post-entry events of the virus life cycle. Absence of cytotoxicity and high viability of treated cells also suggest that S. fusiforme is a potential source of novel naturally occurring antiretroviral compounds that inhibit HIV-1 infection and replication at more than one site of the virus life cycle.
Macrophages and T cells are major targets for HIV-1 infection . While macrophages are key cellular reservoir and a source of newly replicating HIV-1 throughout the infection, a global decline in T cell population leads to the eventual collapse of the immune system, development of clinical manifestations of AIDS, and the ultimate death of the host. Highly active antiretroviral therapy (HAART) has greatly extended the lifespan of HIV-infected individuals, however the AIDS epidemic continues to expand globally and the long-term control of HIV-1 infection remains an elusive goal. Current HAART regiments, with the exception of recent fusion inhibitor (T-20), include inhibitors of two key viral enzymes, reverse transcriptase and protease [2–4]. By using combinations of reverse transcriptase and protease inhibitors in HAART, dramatic reductions in the level of chronic HIV-1 viremia have been achieved in a majority of patients [2, 4]. However, both reverse transcriptase and protease inhibitors have significant clinical side effects [5–7]. Initial optimism that the natural decay of virus-producing cells in the presence of HAART would lead to eradication of virus was short-lived [8, 9]. Long-term follow-up of HAART-treated individuals revealed very slow rates of decline of HIV-1 in some individuals, with continued low-level replication of virus in macrophages and T cells, and viral persistence in several tissue compartments, such as the CNS, not readily accessible to current therapies [5, 9–11]. Studies in a macaque model of simian immunodeficiency virus (SIV) viral persistence in the brain, have suggested that in individuals on HAART with suppressed viral load, the CNS may act as a long-term viral reservoir .
HIV-1 infected human macrophages are the primary route of virus entry into the CNS . Within the CNS, active virus replication is mediated by macrophages and microglia, while astrocytes are nonproductively infected . The number of astrocytes in the brain ranges up to 2 × 1012, and while only 1% of these cells may be latently infected, the total number of infected astrocytes contributing to neuropathology, may be substantial [15, 16]. Brain macrophages, microglia, and astrocytes have been shown to be responsible for some of the neuropathologic manifestations of the HIV-associated dementia (HAD), which develops in about 20–30% of AIDS patients [14, 17]. Although HAART has decreased frequency of HAD, it does not provide full protection or reversal of HAD . Protease inhibitors and some of the nucleoside analogues used in HAART have poor CNS penetration, and drug resistance in this compartment has recently been reported, further underscoring need for discovery of new drugs [12, 19, 20].
Continued virus replication in the presence of HAART increases the likelihood and frequency of generating new multi-drug-resistant (MDR) HIV-1 strains, as demonstrated by the observation that approximately 20% of all new HIV-1 infections are with viruses resistant to the currently available drugs [21, 22]. Consequently, concerted efforts towards the discovery and development of novel inhibitors of HIV-1 infection and replication must persist if continued viral repression and possibility of virus eradication are to be achieved.
We investigated a number of natural products, and identified S. fusiforme extract as a potent inhibitor of HIV-1 replication in T cells, in primary human macrophages, microglia, and astrocytes. While many natural products have been screened for anti-HIV activity [23, 24], including sulfated polysaccharides derived from sea algae [25, 26], S. fusiforme extract has not been investigated up until now .
S. fusiforme does not inhibit cell growth or viability
Based on these results we conclude that treatment with less than 4 mg/ml S. fusiforme extract, does not inhibit cell growth, is not toxic to cells, and is suitable for in vitro testing of HIV-1 inhibition in 1G5 cells.
S. fusiforme inhibits HIV-1 infection in T cells in a dose dependant manner
Based on these results we conclude that S. fusiforme treatment inhibits HIV-1 replication in T cells in a dose dependant manner, inhibition is similar to that achieved with ddC treatment, and treatment is not toxic to cells.
S. fusiforme inhibition is non-toxic and can be sustained over extended periods
In parallel to infection kinetics, we also tested cell viability by trypan blue exclusion assay (Fig. 3B). Cell viability in S. fusiforme treated cultures remained high at 98, 94, and 97% viable cells on day 3, 5, and 7, respectively. Cell viability in ddC treated cultures was similar, and measured 94, 93, and 97% viable cells on day 3, 5, and 7, which was similar to mock treated cultures. This data confirm MTT viability results, which were used to equalize cells to same numbers of viable cells (not shown).
Collectively, these findings demonstrate that S. fusiforme inhibits infection and de novo HIV-1 synthesis, through day 7 of follow-up, and this treatment does not affect cell viability.
S. fusiforme blocks HIV-1 transmission by direct cell-to-cell mechanisms of infection
In the second experiment, we cocultivated HIV infected and untreated 1G5 cells with uninfected and treated HIV-LTR-GFP-expressing GHOST adherent cells , and monitored for cell-to-cell fusion by GFP expression from GHOST cells (G). After cocultivation with infected 1G5 cells, mock or only ddC treated GHOST cells can fuse, and form syncytia that emit green florescence, which was detected by phase fluorescence microscopy. GHOST cells that were ddC treated and cocultivated with HIV-1 infected 1G5 cells, resulted in cell-to-cell fusion and fluorescent giant cell formation as is shown by fluorescence micrograph superimposed on the phase contrast black and white image of the same field (G). However, as in CEM-1G5 cocultivation experiment, no giant cells emitting green fluorescence were detected in 1G5 cells cocultivated with GHOST cells that were treated with S. fusiforme, with or without ddC (not shown).
Based on the results of these two different experiments, we conclude that S. fusiforme blocks HIV-1 infection by cell-to-cell fusion mechanism, which also prevents subsequent multinucleated cell formation and its associated cytophatic effects.
S. fusiforme inhibits HIV-1 infection in primary human macrophages and brain microglia
In infected and untreated macrophage cell cultures, virus levels steadily increased from 19,097 pg of p24/ml on day 4, to a peak of infection on day 14, measuring 163,740 pg of p24/ml, indicating productive HIV-1 infection and de novo virus synthesis (not shown). However, treatment with 1 mg/ml S. fusiforme extract inhibited ADA replication (dark bars) by over 90% through day 14 after infection, which was comparable to the inhibition with ddC treatment (Fig. 5A).
Next, we treated fetal microglial cell cultures with either 1 mg/ml S. fusiforme, or 10-6 M ddC, or mock treated, and monitored infection kinetics by p24 production in cell-free supernatants at the indicated time points after infection (Fig. 5B). As in T cells and macrophages, infected and mock treated microglia were productively infected as demonstrated by steadily increasing p24 production that reached a peak on day 14 with 2,313 pg of p24/ml (not shown). Treatment with S. fusiforme inhibited this infection by 75% on day 3, by over 90% on day 7 and 10, and by 81% on day 14 after infection. By comparison, virus inhibition by ddC was 72% on day 3, and thereafter remained above 90%.
In parallel to infection kinetics, we monitored cell viability by MTT assay, which remained high and was similar to uninfected cell cultures (not shown). Based on these results we conclude that S. fusiforme is a potent inhibitor of R5-tropic HIV-1 infection in primary human macrophages and microglia: inhibition is long lasting, not toxic to cells, and with similar inhibition kinetics to those observed in T cells (Fig. 3A).
S. fusiforme inhibits HIV-1 infection during entry and post-entry events of virus life cycle
Collectively, our results demonstrate that S. fusiforme extract robustly inhibits HIV-1 infection in a number of cell types, and in a number of infection scenarios. In order to determine how this inhibition works, we tested whether the extract could block infection at a post-entry level of virus replication.
To confirm and extend the finding of post-entry inhibition in T cells, we tested for inhibition of VSV/NL4-3 in CD4-negative primary cells. Human astrocytes are CD4-negative cells that are nonproductively infected by HIV-1 in vivo , and in vitro [32–34]. However, we showed that, in vitro, these cells fully support productive virus replication after entry restriction has been bypassed . Infection with VSV/NL4-3 productively infects majority of astrocytes, and serves as model system to study HIV-1 replication in these cells . We infected primary human astrocytes with VSV/NL4-3, and monitored infection kinetics at the indicated time points after infection, by measuring p24 production in cell-free culture supernatants (Fig. 6B). Peak of infection was reached on day 12 with 71,000 pg of p24/ml produced in the infected and untreated cell culture, indicating ongoing virus replication (data not shown). Consistent with post-entry inhibition observed in T cells (Fig. 6A), treatment with 1 mg/ml S. fusiforme extract also inhibited post-entry virus replication in primary human astrocytes, by 71, 40, and 54%, on day 3, 6, and 12, respectively (Fig. 6B).
These data support our hypothesis that in addition to inhibiting viral entry, S. fusiforme extract also blocks viral replication during a post-entry event of the virus life cycle. However, the exact mechanisms of either entry or post-entry inhibition need to be further investigated.
The high rate of HIV-1 mutation and increasing resistance to currently available antiretroviral therapies underscores the need for new antiviral agents. The AIDS pandemic has been especially devastating in the Third world countries that can least afford or have easy access to current therapies, demonstrating a need for affordable treatments aimed at preventing HIV infection . To expand search for novel inhibitors of HIV infection and replication, we studied and identified naturally occurring S. fusiforme extract as an efficient inhibitor of HIV-1 replication in T cells, in primary human macrophages, microglia, and astrocytes.
First, we demonstrated that S. fusiforme aqueous extract does not inhibit cell growth, is not toxic to cells, and was therefore suitable for further in vitro studies of HIV-1 inhibition (Fig. 1). Because it may be easier to block inefficient low level virus replication, we ensured that the observed inhibition was mediated against productive and de novo viral synthesis, by monitoring virus replication by either cell free p24 production or intracellular luciferase reporter gene expression. In T cells, S. fusiforme extract inhibited HIV-1 replication up to 90%, in a dose dependant manner (Fig. 2). This inhibition was long lasting, up to 7 days of follow-up, and was similar to the levels of inhibition observed with ddC treatment (Fig. 3).
In vivo, one mechanism of HIV-1 infection and viral spread is by a direct cell-to-cell fusion, between infected and uninfected cell . To investigate possible inhibition of this mechanism of infection, in two separate experiments with different cell types, we cocultivated S. fusiforme treated cells, with HIV infected cells, and monitored for syncytia formation by microscopy, and for viral replication by luciferase expression (Fig 4). In both experiments, treatment with S. fusiforme, with or without ddC control for free virus infection, prevented cell-to-cell fusion and inhibited infection, in a dose dependant manner. These results demonstrate ability of S. fusiforme to inhibit physiologically relevant mechanism of spreading infection.
Infected macrophages act as a bridge between the periphery and the CNS, by spreading HIV-1 infection to microglia and astrocytes in the CNS . Treatment with 1 mg/ml S. fusiforme extract inhibited active R5-tropic virus replication by 90%, in primary human macrophages and microglial cell cultures (Fig 5). In primary human astrocytes, S. fusiforme ihibited VSV/NL4-3 entry independent infection by 71%, which also suggested post entry inhibition of virus replication in these cells (Fig 6B). S. fusiforme did not inhibit cell growth or viability in these cells, which was consistent with results in T cells (Fig 1 and 2). These results demonstrate ability of S. fusiforme extract to inhibit HIV-1 replication in the two relevant cell types in the CNS, microglia and astrocytes. In this context, it would be of interest to determine whether S. fusiforme is capable of crossing the blood-brain barrier (BBB), and be an effective treatment in this important viral reservoir.
Because it was not clear which step of the virus life cycle S. fusiforme blocks, we investigated possibility of post entry inhibition. We tested for inhibition of infection with VSV-G pseudotyped HIV-1, which has been used to bypasses any entry restrictions [31, 35]. Treatment with increasing doses of S. fusiforme inhibited VSV/NL4-3 infection in T cells in a dose dependant manner (Fig. 6A). However, compared to inhibition of native HIV-1, inhibition of VSV/NL4-3 was markedly lower, up to 57% lower, indicating interference with post entry steps of virus life cycle. We extended this finding by infecting CD4-negative human astrocytes with VSV/NL4-3, which was also inhibited by 71% (Fig 6B). Consistent with lower post entry inhibition in T cells, post entry inhibition in astrocytes was also lower, as compared to 99% inhibition with ddC treatment. The reasons for these inhibition differences are not clear, but given that native NL4-3 has entry restrictions and pseudotyped VSV/NL4-3 does not, we interpret these results to mean that S. fusiforme mediates HIV-1 inhibition during both entry and post entry steps of virus life cycle. However, the exact mechanisms of this inhibition need to be investigated. Considering S. fusiforme inhibition in different cell types, and with different mechanisms of action, we further postulate that this complex aqueous mixture contains more than one biologically active molecule mediating the observed HIV-1 inhibition.
S. fusiforme extract is a potent inhibitor of HIV-1 infection in T cells, in human macrophages, microglia, and astrocytes. Inhibition is mediated during both entry and post entry events of the virus life cycle. Based on these results we propose that S. fusiforme is a lead candidate for bioactivity guided isolation and identification of active compounds mediating the observed HIV-1 inhibition. Identification of these compounds will allow investigation of the precise mechanisms of inhibition as well as standardization of the whole extract for potential in vivo use, and for development of novel antiretroviral drugs and microbicides.
Generation of aqueous extract from S. fusiforme plant material
Dried S. fusiforme was obtained from the wholesale distributor, South Project LTD. Hong Kong, China. To confirm content and consistency, each separate shipment was first identified botanically, and then incubated at 55°C for 6 hours to eliminate any residual moisture. The dried material was briefly washed in cold water to remove any debris or loose particulate matter, weighed and resuspended to 100 mg/ml H20 in covered sterile glass beakers, and boiled at 100°C for one hour. Hot water extracts were allowed to cool to room temperature, then filtered three times through a Whatman filter paper #2, and autoclaved for 20 minutes. Each preparation was centrifuged at 100,000 × g for 1 h to remove any additional particulate matter, aliquoted and stored at -20°C until use.
Cells and culture treatments
1G5 and CEM T cells were obtained from the NIH AIDS Reagent Repository and cultured in RPMI 1640 suplemented with 10% fetal bovine serum (FBS, HyClone) and penicillin-streptomycin (pen/strep).
Monocyte-derived human macrophages
Monocytes were recovered from peripheral blood mononuclear cells (PBMCs) by countercurrent centrifugal elutriation as previously described . Monocytes were cultured as adherent monolayers (1 × 106 cells/well in 24-well plates), differentiated for 7 days in Dulbecco's modified Eagle's medium (DMEM) supplemented with macrophage colony stimulating factor (M-CSF, a generous gift from Wyeth, Cambridge, MA). Confluent cultures of fully differentiated macrophages were infected with HIV-1 CCR5-tropic ADA primary isolate, as indicated in Figure legends.
Isolation and culture of fetal microglial cells
Fetal microglial cells were isolated from second-trimester (gestational age, 17–19 weeks) human fetal brain tissue obtained from elective abortions in full compliance with National Institutes of Health (NIH) guidelines, as previously described . Briefly, the tissue was washed with cold Hanks Balanced Salt Solution (HBSS, MediaTech), then mechanically dissociated and digested with 0.25% trypsin (Gibco) for 30 minutes at 37°C; trypsin was neutralized with FBS (HyClone). Single cell suspensions were plated in DMEM supplemented with 10% FBS, 1000 U/ml M-CSF, and pen/strep. The mixed cultures were maintained at 37°C for 7 days and the media was fully exchanged to remove any cellular debris. The microglial cells, released upon further incubation, were collected and purified by preferential adhesion. Microglia were cultured as adherent monolayers at a density of 0.1 × 106 cells/well in 24-well plates, and were infected as described in Figure legends.
Human fetal astrocytes
Fetal astrocytes were isolated from second-trimester (gestational age, 17–19 weeks) human fetal brains obtained from elective abortions in full compliance with National Institutes of Health (NIH) guidelines, as previously described . Briefly, highly homogenous preparations of astrocytes were obtained using high-density culture conditions in the absence of growth factors in F12 Dulbecco's modified Eagle's medium (GIBCO-BRL, Gaithersburg, Md.) containing 10% FBS, pen/strep, and gentamycin. Cultures were regularly monitored for expression of the astrocytic marker glial fibrillary acidic protein (GFAP) and either HAM56 or CD68 to identify cells of monocyte/macrophage lineage. Only cultures that contained 99% GFAP-positive cells and rare or no detectable HAM56- or CD68-positive cells were used in our experiments .
Cell culture treatments
Before infection, cells were grown for 24 h in culture media with the indicated concentration of either S. fusiforme extract, or with 10-6 M ddC, washed 3 times with HBSS (GIBCO-BRL), and infected as indicated. After infection cells were washed 3 times, and returned to culture with same concentration of each treatment for the duration of experiment.
HIV-1 molecular clones, envelope expression vectors, and generation of pseudotyped HIV-1
T cell tropic HIV-1 molecular clone NL4-3 expresses all known HIV-1 proteins , and it was used to infect T cell experimental systems. VSV/NL4-3 viral stocks were prepared by cotransfection of intact NL4-3 DNA (pNL4-3) and VSV envelope expression vector (pL-VSV-G). The VSV-G expression vector pL-VSV-G was obtained from M. Emerman; it contains a VSV-G insert in the pcDNA expression vector modified by replacing the cytomegalovirus promoter with the HIV-1 long terminal repeat . High-titer virus stocks, including pseudotyped virus, were produced in early passage 293T human embryonic kidney cells transfected with the respective DNA by calcium phosphate precipitation , as previously described . Cell-free viral stocks were tested for HIV-1 p24 core antigen content by enzyme-linked immunosorbent assay (ELISA) using HIV-1 Ag kit as specified by the manufacturer (Coulter, Hialeah, Fla). Titers of infectious virus were determined by multinuclear activation of β-galactosidase indicator (MAGI) assay . In our hands, a multiplicity of infection of 1 for CD4-positive T cells is equivalent to approximately 1 pg of viral p24 per cell . Macrophage and microglial cells infections were performed using the HIV-1 CCR5-tropic primary isolate ADA, as previously described .
Infections and analysis of HIV-1 expression by luciferase gene expression and by p24 ELISA
T cells, confluent cultures of macrophages, microglial cells, or human fetal astrocytes were infected with native or pseudotyped HIV-1 at the multiplicity of infection (moi) as indicated in the Figure legends, and were washed three times with HBSS (GIBCO-BRL) before being returned to culture. At the indicated times after infection, equal number of viable cells normalized by CellTiter 96 Non-Radioactive Cell proliferation Assay [(3-(4,5-Dimethyl-2-thiazolyl)-2,5-dephenyltetrazolium (MTT)] kit, or by trypan blue exclusion assay, were tested for luciferase expression using Luciferase Assay System kit (Promega) as specified by the manufacturer. Cell-free supernatants were tested for HIV-1 p24 core antigen content by ELISA using the HIV-1 Ag kit as specified by the manufacturer (Coulter, Hialeah, Fla).
Infected T cell cultures were analyzed for syncytium formation at the indicated time points after infection by visualizing cells under an Olympus BH-2 fluorescence microscope, and at least 4 separate wells from a 12-well plate (Costar), from identical experimental systems were analyzed.
Calculation of percent inhibition of infection
Percent (%) inhibition was determined from either luciferase expression or p24 content, utilizing the following formula:
We thank Dr. Carlos de Noronha for technical help with cell-to-cell fusion experiments, useful comments and discussion, and editorial help. This work was supported by NIH grant RO1-NS-40666, and The Campbell Foundation grant to MC.
- Levy JA: HIV and the pathogenesis of AIDS. 1998, Washington DC, AMS, second edition.Google Scholar
- Bushman F, Landau NR, Emini EA: New developments in the biology and treatment of HIV. Proc Natl Acad Sci U S A. 1998, 95: 11041-11042. 10.1073/pnas.95.19.11041PubMed CentralView ArticlePubMedGoogle Scholar
- Cohen OJ, Fauci AS: Current strategies in the treatment of HIV infection. Adv Intern Med. 2001, 46: 207-246.PubMedGoogle Scholar
- Powderly WG: Current approaches to treatment for HIV-1 infection. J Neurovirol. 2000, 6 Suppl 1: S8-S13.PubMedGoogle Scholar
- Volberding PA: Advances in the medical management of patients with HIV-1 infection: an overview. Aids. 1999, 13 Suppl 1: S1-9.PubMedGoogle Scholar
- Graham NM: Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr. 2000, 25 Suppl 1: S4-11. 10.1097/00042560-200010001-00002View ArticlePubMedGoogle Scholar
- Moyle G: Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther. 2000, 22: 911-36; discussion 898. 10.1016/S0149-2918(00)80064-8View ArticlePubMedGoogle Scholar
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996, 271: 1582-1586.View ArticlePubMedGoogle Scholar
- Chun TWSLMSBELAMJAMBMLALNMAFAS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997, 94: 13193-13197. 10.1073/pnas.94.24.13193PubMed CentralView ArticlePubMedGoogle Scholar
- Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997, 387: 183-188. 10.1038/387183a0View ArticlePubMedGoogle Scholar
- Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997, 278: 1291-1295. 10.1126/science.278.5341.1291View ArticlePubMedGoogle Scholar
- Clements JE, Li M, Gama L, Bullock B, Carruth LM, Mankowski JL, Zink MC: The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol. 2005, 11: 180-189. 10.1080/13550280590922829View ArticlePubMedGoogle Scholar
- Gartner S: HIV infection and dementia. Science. 2000, 287: 602-604. 10.1126/science.287.5453.602View ArticlePubMedGoogle Scholar
- Gendelman HE, Grant I, Everall I, Lipton AS, Swindells S: The Neurology of AIDS. Edited by: Gendelman HE, Grant I, Everall I, Lipton AS and Swindells S. 2005, Oxford, Oxford University Press, Second Edition.Google Scholar
- Rutka JT, Murakami M, Dirks PB, Hubbard SL, Becker LE, Fukuyama K, Jung S, Tsugu A, Matsuzawa K: Role of glial filaments in cells and tumors of glial origin: a review. J Neurosurg. 1997, 87: 420-430.View ArticlePubMedGoogle Scholar
- Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD: Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol. 1996, 39: 705-711. 10.1002/ana.410390606View ArticlePubMedGoogle Scholar
- McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP: Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993, 43: 2245-2252.View ArticlePubMedGoogle Scholar
- Kaul M, Garden GA, Lipton SA: Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001, 410: 988-994. 10.1038/35073667View ArticlePubMedGoogle Scholar
- Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P: Antiretroviral drugs and the central nervous system. Aids. 1998, 12: 1941-1955.View ArticlePubMedGoogle Scholar
- Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B: Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. Aids. 2000, 14: 1949-1954. 10.1097/00002030-200009080-00010View ArticlePubMedGoogle Scholar
- Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B: Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. Aids. 2000, 14: 1009-1015. 10.1097/00002030-200005260-00013View ArticlePubMedGoogle Scholar
- Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002, 347: 385-394. 10.1056/NEJMoa013552View ArticlePubMedGoogle Scholar
- Cowan MM: Plant products as antimicrobial agents. Clin Microbiol Rev. 1999, 12: 564-582.PubMed CentralPubMedGoogle Scholar
- Yang SS, Cragg GM, Newman DJ, Bader JP: Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J Nat Prod. 2001, 64: 265-277. 10.1021/np0003995View ArticlePubMedGoogle Scholar
- Witvrouw M, De Clercq E: Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol. 1997, 29: 497-511. 10.1016/S0306-3623(96)00563-0View ArticlePubMedGoogle Scholar
- Hoshino T, Hayashi T, Hayashi K, Hamada J, Lee JB, Sankawa U: An antivirally active sulfated polysaccharide from Sargassum horneri (TURNER) C. AGARDH. Biol Pharm Bull. 1998, 21: 730-734.View ArticlePubMedGoogle Scholar
- Schaeffer DJ, Krylov VS: Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol Environ Saf. 2000, 45: 208-227. 10.1006/eesa.1999.1862View ArticlePubMedGoogle Scholar
- Aguilar-Cordova E, Chinen J, Donehower L, Lewis DE, Belmont JW: A sensative reporter cell line for HIV-1 tat activity, HIV-1 Inhibitors, and T cell activation effects. Aids research and human retroviruses. 1994, 10: 295-301.View ArticlePubMedGoogle Scholar
- Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyo EM, Bjorling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol. 1999, 73: 2343-2349.PubMed CentralPubMedGoogle Scholar
- Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS, Skillman D, Meltzer MS: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor-1 treated monocytes. J Exp Med. 1988, 167: 1428-1441. 10.1084/jem.167.4.1428View ArticlePubMedGoogle Scholar
- Matlin KS, Reggio H, Helenius A, Simons K: Pathway of vesicular stomatitis virus entry leading to infection. J Mol Biol. 1982, 156: 609-631. 10.1016/0022-2836(82)90269-8View ArticlePubMedGoogle Scholar
- Tornatore C, Meyers K, Atwood W, Conant K, Major E: Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes. J Virol. 1994, 68: 93-102.PubMed CentralPubMedGoogle Scholar
- Canki M, Potash MJ, Bentsman G, Chao W, Flynn T, Heinemann M, Gelbard H, Volsky DJ: Isolation and long-term culture of primary ocular human immunodeficiency virus type 1 isolates in primary astrocytes. J Neurovirol. 1997, 3: 10-15.View ArticlePubMedGoogle Scholar
- Bencheikh M, Bentsman G, Sarkissian N, Canki M, Volsky JD: Replication of different clones of human immunodeficiency virus type 1 in primary human fetal astrocytes: enhancment of viral gene expression by Nef. Journal NeuroVirology. 1999, 5: 115-124.View ArticleGoogle Scholar
- Canki M, Thai JNF, Chao W, Ghorpade A, Potash MJ, Volsky DJ: Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes. J Virol. 2001, 75: 7925-7933. 10.1128/JVI.75.17.7925-7933.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Piot P: AIDS: a global response. Science. 1996, 272: 1855-View ArticlePubMedGoogle Scholar
- Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993, 57: 183-289.PubMed CentralPubMedGoogle Scholar
- Adachi A, Gendelman HE, koening S, Folks T, Willey R, Rabson A, Martin M: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology. 1986, 59: 284-291.PubMed CentralPubMedGoogle Scholar
- Bartz RS, Vodicka AM: Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. y. 1997, 12: 337-342.Google Scholar
- Ausubel MF, Brent R, Kingston ER, Moore DD, Seidman GJ, Smith AJ, Struhl K: Current protocols in molecular biology. 1995, New York, N.Y., John Wiley & Sons, Inc.Google Scholar
- Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992, 66: 2232-2239.PubMed CentralPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.